Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

ProStrakan press release on Rectogesic: β€˜aiding healing’ claim ruled inaccurate (Clauses 9.1, 20.2); no promotion breach

A public complaint challenged a Rectogesic press release implying it aided fissure healing. PMCPA ruled the statement inaccurate…

8 Mar 2026

Anonymous v Merck Sharp & Dohme: Cerazette Discount Scheme (AUTH/2613/6/13)

PMCPA case AUTH/2613/6/13 about a Cerazette discount scheme. The matter was found to be outwith the scope of…

8 Mar 2026

GSK voluntary admission: out-of-date prescribing information used in Avandamet ads (AUTH/1922/11/06)

GSK disclosed that Avandamet ads ran for ~3 months with outdated prescribing information omitting macular oedema as a…

8 Mar 2026

Biogen Idec: Imraldi aRMMs sent by recorded delivery to a doctor’s home address (AUTH/3121/11/18)

A hospital doctor said an Imraldi mailing requiring a signature was harassment and an inappropriate marketing practice. Panel…

8 Mar 2026

AUTH/3332/4/20: Anonymous v Sobi β€” unsolicited MSL β€œmaking contact” email during COVID-19 (No breach)

Anonymous complaint about an unsolicited MSL email to an NHS address during COVID-19. Panel found the email was…

8 Mar 2026

AUTH/3425/11/20 & AUTH/3426/11/20: RCGP Overdiagnosis Group complaint about Eliquis AF pulse-check email (No breach)

RCGP Overdiagnosis Group challenged a Pfizer/BMS Eliquis email promoting AF pulse checks at flu clinics for over-65s, alleging…

8 Mar 2026

LEO Pharma voluntary admission: undisclosed 2019 transfers of value to patient organisations (AUTH/3527/6/21)

LEO discovered four cross-border transfers of value involving three UK patient organisations. Three 2019 payments were disclosed late…

8 Mar 2026

Teva: Ajovy website landing-page pop-up – no breach (AUTH/3602/1/22)

A UK health professional complained that the Ajovy website entry pop-up lacked the generic name and black triangle.…

8 Mar 2026

AstraZeneca breach over Trixeo ad implying mortality benefit (Pulse magazine)

Pulse ad for Trixeo linked COPD exacerbations and death with a β€œTake action with Trixeo” call-to-action, creating an…

8 Mar 2026

AUTH/3728/1/23: Complainant v Bristol Myers Squibb – alleged promotion of Zeposia (ozanimod hydrochloride) (No breach / not within scope)

PMCPA case AUTH/3728/1/23: complaint alleging promotion of Zeposia (ozanimod hydrochloride) against Bristol Myers Squibb. Outcome: no breach; matter…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training